+39 02 610346.1 - info@newron.com

Success in CNS drug development – Innovation in Rare Diseases

We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Our shares are listed on the SIX Swiss Exchange (NWRN).

Latest press releases

  • 31Mar
    Newron AGM Result and Clinical and Business Update

     

  • 11Mar
    Newron updates on STARS study FDA interaction

     

  • 5Mar
    Newron announces 2019 financial results and provides outlook for 2020

     

  • 17Feb
    Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia

     

  • 4Feb
    Newron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New York

  • 9Jan
    Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA

     

View All

Newron share price

Events

  • 22Apr
    PLATOW BörsenFORUM 2020

    April 22, 2020 - Frankfurt am Main, Germany

  • 13Sep
    H.C. Wainwright 22nd Annual Global Investment Conference

    September 13-15, 2020 - New York, NY, USA 

  • 15Sep
    Swiss Biotech Day 2020

    September 15, 2020 - Basel, Switzerland 

View Event Calendar